By Brian Dolan March 14, 2013
There has been a painfully slow chess game playing out in Washington DC these past two years over the fate of FDA regulation of mobile medical apps. Last July I wrote about the largely failed attempt by some members of Congress and companies like Aetna, UnitedHealth, and Verizon Communications to insert language into the The Food and Drug Administration Safety and Innovation Act (FDASIA) to slow...

Editor's Pick